Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms
2019
The identification of JAK-STAT pathway mutations in the majority of patients with myeloproliferative neoplasms (MPN) led to the clinical development of JAK inhibitors and resulted in the approval of ruxolitinib for MPN therapy.
Despite this important therapeutic advancement, there are significant
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
15
References
0
Citations
NaN
KQI